Akums Drugs Receives ESG Rating of "65" from NSE Sustainability
Akums Drugs and Pharmaceuticals Limited (AKUMS) received an ESG rating of "65" for FY 2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was voluntarily assigned on September 02, 2026, based on publicly available data.
Receiving an ESG rating is a routine disclosure and does not immediately impact the company's financial performance or operational strategy. The impact is considered low unless further details on the implications of this rating are provided.
The announcement is a factual disclosure of an ESG rating received by the company. It does not contain any performance indicators or forward-looking statements that would suggest a positive or negative sentiment.
Akums Drugs and Pharmaceuticals Limited (AKUMS) has received an ESG rating of "65" for the Financial Year 2025-26 from NSE Sustainability Ratings & Analytics Limited. This rating was voluntarily assigned by NSE Sustainability, a subsidiary of NSE Indices Limited, based on publicly available information. The company did not engage NSE Sustainability for this rating.
The ESG rating was received on September 02, 2026. The link to the ESG rating is https://www.nse-esgrating.com/esg-ratings/552?fiscalYear=2024-2025. This information is provided pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
A plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.